Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Urologic ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global burden of urologic cancers, 1990–2013.Eur Urol. 2017; 71: 437-446
- PET imaging for prostate cancer.Radiologic Clin. 2021; 59: 801-811
- Prostate cancer diagnostics: Clinical challenges and the ongoing need for disruptive and effective diagnostic tools.Biotechnol Adv. 2017; 35: 135-149
- Imaging biomarkers in prostate cancer: role of PET/CT and MRI.Eur J Nucl Med Mol Imaging. 2015; 42: 644-655
- Molecular imaging of prostate cancer.Radiographics. 2016; 36: 142
- Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique.Histopathology. 2007; 50: 472-483
- Intra-individual comparison of 68 Ga-PSMA-11 and 18 F-DCFPyL normal-organ biodistribution.Cancer Imaging. 2019; 19: 1-10
- 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis.Eur Urol focus. 2018; 4: 686-693
- 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.Eur J Nucl Med Mol Imaging. 2017; 44: 941-949
- Can 68Ga-prostate specific membrane antigen positron emission tomography/computerized tomography provide an accurate lymph node staging for patients with medium/high risk prostate cancer? A diagnostic meta-analysis.Radiat Oncol. 2020; 15: 1-10
- The meta-analysis of the effect of 68Ga-PSMA-PET/CT diagnosis of prostatic cancer compared with bone scan.Medicine. 2021; 100
- Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends.Cancers. 2021; 13: 5360
- Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: Results from the CONDOR phase III, multicenter study.Clin Cancer Res. 2021; 27: 3674-3682
- A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY).J Urol. 2021; 206: 52-61
- Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis.Front Oncol. 2021; 11: 649171
- Diagnostic role of 18F-PSMA-1007 PET/CT in prostate cancer staging: a systematic review.Diagnostics. 2021; 11: 552
- F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.Eur J Nucl Med Mol Imaging. 2017; 44: 678-688
- Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer.Urology. 1999; 54: 1058-1063
- Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC).Journal of Clinical Oncology. 2013; 31: 31
- A Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor–Positive Prostate Cancer.J Nucl Med. 2022; 63: 424-430
- In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548.Clin Cancer Res. 2013; 19: 5434-5443
- Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography/computed tomography imaging of newly diagnosed prostate cancer.Eur Urol Oncol. 2019; 2: 166-173
- Detection of prostate cancer with the [68Ga]-labeled bombesin antagonist RM2 in patients undergoing radical prostatectomy.Journal of Clinical Oncology. 2016; 34: 80
- A prospective study of 68Ga-RM2 PET/MRI in patients with biochemically recurrent prostate cancer and negative conventional imaging.Journal of Clinical Oncology. 2020; 38: e17536
- Detection of additional primary neoplasms on 18F-Fluciclovine PET/CT in patients with primary prostate cancer.J Nucl Med. 2021; 63: 713-719
- 18F-Facbc in prostate cancer: a systematic review and meta-analysis.Cancers. 2019; 11: 1348
- Review of 18F-fluciclovine PET for detection of recurrent prostate cancer.Radiographics. 2019; 39: 822-841
- 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.Lancet Oncol. 2019; 20: 1286-1294
- Clinical PET imaging in prostate cancer.Radiographics. 2017; 37: 1512-1536
- Is There Use for FDG-PET in Prostate Cancer?.Semin Nucl Med. 2016; 46: 502-506
- Incidental uptake of 18F-fluorodeoxyglucose in the prostate gland.Nuklearmedizin-NuclearMedicine. 2014; 53: 249-258
- The evolving role of 18F-FDG PET/CT in diagnosis and prognosis prediction in progressive prostate cancer.Front Oncol. 2021; 11: 683793
- The use of hyperpolarised 13C-MRI in clinical body imaging to probe cancer metabolism.Br J Cancer. 2021; 124: 1187-1198
- Hyperpolarised 13C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancer.Nat Commun. 2022; 13: 1-12
- Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study.Prostate Cancer prostatic Dis. 2020; 23: 269-276
- Prostate cancer: PET with 18F-FDG, 18F-or 11C-acetate, and 18F-or 11C-choline.J Nucl Med. 2011; 52: 81-89
- Comparative studies of radiolabeled choline positron emission tomography, histology of primary tumor and other imaging modalities in prostate cancer: a systematic review and meta-analysis.Clin Translational Imaging. 2013; 1: 99-109
- Accumulation of [11C] acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer.Eur J Nucl Med Mol Imaging. 2002; 29: 1492-1495
- Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature.BJU Int. 2013; 112: 1062-1072
- 11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction.J Nucl Med. 2013; 54: 699-706
- 11C-acetate-PET/CT compared to 99mTc-HDP bone Scintigraphy in primary staging of high-risk prostate cancer.Anticancer Res. 2016; 36: 6475-6479
- Evaluation of prostate cancer bone metastases with 18F-NaF and 18F-fluorocholine PET/CT.J Nucl Med. 2016; 57: 55S-60S
- 18F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies.Ann Nucl Med. 2019; 33: 351-361
- Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review.J Clin Med. 2021; 10: 4909
- Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.Radiology. 2014; 271: 220-229
- Tumor localization of 16β-18F-fluoro-5α-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer.J Nucl Med. 2004; 45: 366-373
- Positron tomographic assessment of androgen receptors in prostatic carcinoma.Eur J Nucl Med Mol Imaging. 2005; 32: 344-350
- First-in-human uPAR PET: imaging of cancer aggressiveness.Theranostics. 2015; 5: 1303
- Urokinase-type plasminogen activator receptor (uPAR) PET/MRI of prostate cancer for noninvasive evaluation of aggressiveness: comparison with Gleason score in a prospective phase 2 clinical trial.J Nucl Med. 2021; 62: 354-359
- Prostatic carcinoma cell migration via αvβ3integrin is modulated by a focal adhesion kinase pathway.Cancer Res. 1999; 59: 1655-1664
- Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PET.Oncotarget. 2016; 7: 28151
- Non-invasive molecular imaging of kidney diseases.Nat Rev Nephrol. 2021; 17: 688-703
- Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.Eur Urol. 2010; 58: 75-83
- Targeted PET/CT imaging for clear cell renal cell carcinoma with radiolabeled antibodies: recent developments using girentuximab.Curr Opin Urol. 2021; 31: 249-254
- Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial.Lancet Oncol. 2007; 8: 304-310
- Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with 111In-girentuximab.Eur J Nucl Med Mol Imaging. 2020; 47: 1864-1870
- Positron emission tomography/computed tomography with 89Zr-girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion.Eur Urol. 2018; 74: 257-260
- PET/CT imaging of renal cell carcinoma with 18F-VM4-037: a phase II pilot study.Abdom Radiol. 2016; 41: 109-118
- Early assessment with 18 F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab.BMC cancer. 2019; 19: 1-9
- Meta-analysis of the diagnostic performance of [18F] FDG-PET and PET/CT in renal cell carcinoma.Cancer Imaging. 2012; 12: 464
- Prognostic value of pretreatment metabolic tumor volume and total lesion glycolysis using 18F-FDG PET/CT in patients with metastatic renal cell carcinoma treated with anti–vascular endothelial growth factor–targeted agents.Clin Nucl Med. 2017; 42: e235-e241
- Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT.Ann Nucl Med. 2015; 29: 877-882
- Inconsistent detection of sites of metastatic non-clear cell renal cell carcinoma with PSMA-targeted [18F] DCFPyL PET/CT.Mol Imaging Biol. 2019; 21: 567-573
- Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience.Eur J Nucl Med Mol Imaging. 2017; 44: 102-107
- Metabolic imaging with hyperpolarized 13C pyruvate magnetic resonance imaging in patients with renal tumors—Initial experience.Cancer. 2021; 127: 2693-2704
- Hyperpolarized 13C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma—A Proof of Principle Study.Cancers. 2022; 14: 335
- Diagnostic performance of 11C-choline PET/CT and FDG PET/CT for staging and restaging of renal cell cancer.Ann Nucl Med. 2018; 32: 658-668
- Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.Clin Cancer Res. 2011; 17: 7634-7644
- FDG and FLT-PET for early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.Cancer Imaging. 2015; 15: 1-10
- Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.Ann Oncol. 2015; 26: 2113-2118
- 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.J Nucl Med. 2010; 51: 1707-1715
- 89Zr-bevacizumab PET: potential early indicator of everolimus efficacy in patients with metastatic renal cell carcinoma.J Nucl Med. 2017; 58: 905-910
- 18F-FPRGD2 PET/CT imaging of integrin αvβ3 in renal carcinomas: correlation with histopathology.J Nucl Med. 2015; 56: 361-364
- [18F] Fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ3 and αvβ5 integrins.Eur J Nucl Med Mol Imaging. 2014; 41: 1879-1888
- The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis.World J Urol. 2016; 34: 1229-1237
- Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis.World J Urol. 2019; 37: 667-690
- Diagnostic accuracy of F-18 FDG PET/CT for preoperative lymph node staging in newly diagnosed bladder cancer patients: a systematic review and meta-analysis.Oncology. 2018; 95: 31-38
- FDG-PET/CT for assessing the response to neoadjuvant chemotherapy in bladder cancer patients.Clin Genitourinary Cancer. 2018; 16: 360-364
- Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study.Abdom Radiol. 2018; 43: 2391-2399
- Diagnostic accuracy of C-11 choline and C-11 acetate for lymph node staging in patients with bladder cancer: a systematic review and meta-analysis.World J Urol. 2018; 36: 331-340
- Initial results with 11C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer.Mol Imaging Biol. 2012; 14: 245-251
- Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis.Biomed Res Int. 2014; 2014: 852681
- Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosis of upper urinary tract urothelial carcinoma.Int J Clin Oncol. 2015; 20: 1042-1047
- Clinical value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in upper tract urothelial carcinoma: impact on detection of metastases and patient management.Urologia Internationalis. 2016; 96: 65-72
Article info
Identification
Copyright
© 2022 Published by Elsevier Inc.
